DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026
WASHINGTON, May 15, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, announced the
{fullname}
About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts
Related posts
---
SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation
SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Feb. 1, 2024
---
DeepQure Advances Global Clinical Trials for Innovative RDN Technology
SEOUL, South Korea, March 4, 2025 /PRNewswire/ -- Breaking Barriers in Hypertension Treatment DeepQure Inc.,
---
NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes
An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated
---
BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints
SUZHOU, China, May 5, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred
---
Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion
VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ -- WAT Medical Enterprise collaborated with Concordia University
